IBSRELA – Dec Display Banners Peer to Peer – 55457

Lin Chang, MD, AGAF spoke with Physician’s Weekly about the guideline and the overall topic of pharmacological management of IBS-C.

Physician’s Weekly recently spoke with Linda Girgis, MD, FAAFP, about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, lead author of the phase 3 T3MPO-2 study—which assessed the efficacy of the NHE3 inhibitor tenapanor in treating patients with irritable bowel syndrome with constipation (IBS-C)—about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with Lin Chang, MD, AGAF, lead author of the 2022 AGA Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation (IBS-C).

Physician’s Weekly recently spoke with Brooks Cash, MD about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with Satish SC Rao, MD, PhD, FRCP, FACG, AGAF about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.

Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, the lead author...

Physician’s Weekly recently spoke with Brian E. Lacy, MD, PhD,  a board-certified...